» Articles » PMID: 14750902

Repression of Smad4 Transcriptional Activity by SUMO Modification

Overview
Journal Biochem J
Specialty Biochemistry
Date 2004 Jan 31
PMID 14750902
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Smad4 plays a key role in TGF-beta (transforming growth factor beta)/Smad-mediated transcriptional responses. We show that Smad4 is sumoylated both in vivo and in vitro. Recent studies showed that sumoylation of Smad4 regulated its stability, but the effect of sumoylation on the intrinsic transcriptional activity of Smad4 was not defined. We show that overexpression of SUMO (small ubiquitin-related modifier)-1 and Ubc9 can inhibit a TGF-beta-responsive reporter gene, whereas co-transfection with SUMO-1 protease-1 (SuPr-1) can increase the TGF-beta response. We show further that mutation of the Smad4 sumoylation sites or co-transfection with SuPr-1 greatly increases Smad4 transcriptional activity. Moreover, direct fusion of SUMO-1 to the sumoylation mutant Smad4 potently inhibits its transcriptional activity. Thus, as it is being rapidly discovered that sumoylation inhibits the activities of many transcription factors, sumoylation also represses Smad4 transcriptional activity. The net effect of sumoylation of Smad4 can therefore be either stimulatory or inhibitory, depending on the target promoter that is analysed.

Citing Articles

Exploring potential targets for natural product therapy of DN: the role of SUMOylation.

Wang J, Zhang R, Wu C, Wang L, Liu P, Li P Front Pharmacol. 2024; 15:1432724.

PMID: 39431155 PMC: 11486755. DOI: 10.3389/fphar.2024.1432724.


TGF‑β/Smad signaling in chronic kidney disease: Exploring post‑translational regulatory perspectives (Review).

Li J, Zou Y, Kantapan J, Su H, Wang L, Dechsupa N Mol Med Rep. 2024; 30(2).

PMID: 38904198 PMC: 11208996. DOI: 10.3892/mmr.2024.13267.


N6-methyladenosine modification and post-translational modification of epithelial-mesenchymal transition in colorectal cancer.

Wang Y, Chen Y, Zhao M Discov Oncol. 2024; 15(1):209.

PMID: 38834851 PMC: 11150216. DOI: 10.1007/s12672-024-01048-3.


SUMO-dependent transcriptional repression by Sox2 inhibits the proliferation of neural stem cells.

Marelli E, Hughes J, Scotting P PLoS One. 2024; 19(3):e0298818.

PMID: 38507426 PMC: 10954124. DOI: 10.1371/journal.pone.0298818.


Paradoxes of Cellular SUMOylation Regulation: A Role of Biomolecular Condensates?.

Cheng X, Yang W, Lin W, Mei F Pharmacol Rev. 2023; 75(5):979-1006.

PMID: 37137717 PMC: 10441629. DOI: 10.1124/pharmrev.122.000784.


References
1.
Lee P, Chang C, Liu D, Derynck R . Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. J Biol Chem. 2003; 278(30):27853-63. DOI: 10.1074/jbc.M301755200. View

2.
Lin X, Liang M, Liang Y, Brunicardi F, Melchior F, Feng X . Activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4. J Biol Chem. 2003; 278(21):18714-9. DOI: 10.1074/jbc.M302243200. View

3.
Lin X, Liang M, Liang Y, Brunicardi F, Feng X . SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. J Biol Chem. 2003; 278(33):31043-8. DOI: 10.1074/jbc.C300112200. View

4.
Long J, Matsuura I, He D, Wang G, Shuai K, Liu F . Repression of Smad transcriptional activity by PIASy, an inhibitor of activated STAT. Proc Natl Acad Sci U S A. 2003; 100(17):9791-6. PMC: 187844. DOI: 10.1073/pnas.1733973100. View

5.
Liu F . Receptor-regulated Smads in TGF-beta signaling. Front Biosci. 2003; 8:s1280-303. DOI: 10.2741/1149. View